Thayer School of Engineering, Dartmouth, Hanover, NH, USA.
Lyticon LLC, Lebanon, NH, USA.
FEBS Open Bio. 2021 Mar;11(3):705-713. doi: 10.1002/2211-5463.13094. Epub 2021 Feb 5.
Combinations of human lysozyme (hLYS) and antimicrobial peptides (AMPs) are known to exhibit either additive or synergistic activity, and as a result, they have therapeutic potential for persistent and antibiotic-resistant infections. We examined hLYS activity against Pseudomonas aeruginosa when combined with six different AMPs. In contrast to prior reports, we discovered that some therapeutically relevant AMPs manifest striking antagonistic interactions with hLYS across particular concentration ranges. We further found that the synthetic AMP Tet009 can inhibit hLYS-mediated bacterial lysis. To the best of our knowledge, these results represent the first observations of antagonism between hLYS and AMPs, and they advise that future development of lytic enzyme and AMP combination therapies considers the potential for antagonistic interactions.
人溶菌酶(hLYS)和抗菌肽(AMPs)的组合已知表现出相加或协同作用,因此它们具有治疗持久性和抗药性感染的潜力。我们研究了 hLYS 与六种不同 AMP 结合时对铜绿假单胞菌的活性。与先前的报告相反,我们发现一些治疗相关的 AMP 在特定浓度范围内与 hLYS 表现出明显的拮抗相互作用。我们进一步发现合成 AMP Tet009 可以抑制 hLYS 介导的细菌裂解。据我们所知,这些结果代表了 hLYS 和 AMP 之间拮抗作用的首次观察结果,并建议未来开发裂解酶和 AMP 联合治疗时考虑潜在的拮抗相互作用。